The campaign to use so-called march-in rights to widen access to a cancer drug is getting personal.
Universities Allied for Essential Medicines, one of several advocacy groups backing the use of a controversial U.S. law to counter high drug prices, is arguing that an official at the National Institutes of Health should be recused from any decision-making role in responding to a petition to sidestep patents for the Xtandi prostate cancer drug.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
